Use of Tinzaparin for Anticoagulation in Hemodialysis
Overview
The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.
Full Title of Study: “Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Prevention
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: September 2016
Interventions
- Drug: Tinzaparin
- Drug: Unfractionated Heparin
- Drug: Placebo (for Tinzaparin)
- 0.9% Normal Saline
- Drug: Placebo (for Unfractionated Heparin)
- 0.9% Normal Saline
Arms, Groups and Cohorts
- Experimental: Tinzaparin
- Active Comparator: Unfractionated Heparin
Clinical Trial Outcome Measures
Primary Measures
- Rate of major, clinically important non-major or minor bleeding
- Time Frame: 26 weeks
Secondary Measures
- Clotting in extracorporeal dialysis circuit
- Time Frame: During Hemodialysis (weekly for 26 weeks)
Participating in This Clinical Trial
Inclusion Criteria
- Age >= 18 years – End stage renal disease maintained on outpatient hemodialysis for >= 3 months – Frequency of hemodialysis: 3 times per week – Anticoagulation with an unfractionated heparin protocol for at least 4 weeks – Patient or legal guardian able to provide written consent – Baseline INR <= 1.3 – Baseline platelet count >= 80,000 x 10^9/L Exclusion Criteria:
- Therapeutic systemic anticoagulation – Clinically apparent bleeding in the last 2 months – High risk of bleeding – Planned major surgery in the next 4 months – Major surgery in the past 48 hours – Pregnant or lactating – Child bearing potential – Allergy/intolerance to heparin or history of heparin induced thrombocytopenia – Current participation in a related randomized drug trial
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Christine Ribic
- Collaborator
- McMaster University
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Christine Ribic, Nephrologist – St. Joseph’s Healthcare Hamilton
- Overall Official(s)
- Dr. Christine M Ribic, MD, MSc, Principal Investigator, St. Joseph’s Healthcare Hamilton/McMaster University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.